Velarion · Company Intelligence
CompBrief
Fiscal year 2025

Vipin Garg — FY2025 total compensation $8,026,590

Vipin Garg is Chief Executive Officer of Altimmune, Inc. (ALT). The company reported total compensation of $8,026,590 for fiscal year 2025.

01

Fiscal year 2025 compensation

Salary$658,694
Bonus$1,000
Stock awards$1,153,600
Option awards$4,812,167
Non-equity incentive plan$357,753
Pension and non-qualified deferred compensation$0
All other compensation$1,043,376
Total$8,026,590

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.

Cited to the compensation disclosure Altimmune, Inc. filed March 17, 2026, accession 0001104659-26-028953.

02

History — every fiscal year held

Fiscal yearRoleSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
FY2025Chief Executive Officer$658,694$1,000$1,153,600$4,812,167$357,753$0$1,043,376$8,026,590
FY2024Chief Executive Officer$633,360$0$1,560,896$3,536,567$330,931$0$28,708$6,090,462

Totals as disclosed in each year's own compensation disclosure for Altimmune, Inc..

03

Peer context

Peer-group chief executive median$3,456,253
Difference from that median$4,570,337
Percentile within the disclosed peer group88th
Peers with a disclosed figure17

Medians and percentiles are computed across the peer group Altimmune, Inc. discloses in its own compensation disclosure.

04

The other named executive officers of Altimmune, Inc.

Named executive officerRoleFY2025 total
Vipin Garg this pageChief Executive Officer$8,026,590
M. Scott Harrisformer Chief Medical Officer$2,631,071
Christophe Arbet-EngelsChief Medical Officer$2,329,895
M. Scot RobertsChief Scientific Officer$2,182,996

The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Altimmune, Inc. compensation brief.

05

The company page

Vipin Garg's compensation sits inside Altimmune, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.

The Altimmune, Inc. (ALT) compensation brief